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A B S T R A C T   
Tissue barriers limit drug delivery in the eye. Therefore, retinal diseases are treated with intravitreal injections. 
Delivery systems with reduced dosing frequency and/or cellular drug delivery properties are needed. We present 
here a modular peptide-based delivery system for cell targeted release of dexamethasone in the retinal pigment 
epithelial cells. The peptide–dexamethasone conjugates consist of cell penetrating peptide, enzyme cleavable 
linker and dexamethasone that is conjugated with hydrazone bond. The conjugates are chemically stable in the 
vitreous, internalize into the retinal pigment epithelial cells and release dexamethasone intracellularly by en-
zymatic action of cathepsin D. In vitro binding assay and molecular docking confirm binding of the released 
dexamethasone fragment to the human glucocorticoid receptor. In vivo rabbit studies show increased vitreal 
retention of dexamethasone with a peptide conjugate. Modular peptide conjugates are a promising approach for 
drug delivery into the retinal cells.   
1. Introduction 
Ocular drug delivery poses significant challenges due to the unique 
anatomy and physiology of the eye. Various static and dynamic barriers 
limit efficient drug delivery, particularly to the posterior segment of the 
eye [1–3]. Therapeutic intervention of the posterior segment is crucial 
for many vision-threatening diseases, such as age-related macular de-
generation, glaucoma, macular edema, diabetic retinopathy, and 
uveitis. These diseases cause disorders in the retina and choroid, 
thereby leading to impaired vision and blindness in millions of patients 
worldwide. 
Topical eye drops are useful in the treatment of anterior segment 
diseases in the eye but they are ineffective in the treatment of retinal 
diseases. Several tissue barriers and flow factors limit drug distribution 
from topical application site to posterior segment tissues [4–6]. Tight 
tissue barriers between blood stream and ocular compartments (ante-
rior, posterior) prevent drug distribution from the blood circulation into 
the ocular drug target tissues [7]. Alternative modes of ocular drug 
administration, such as sub-conjunctival, suprachoroidal, and perio-
cular injections, have only achieved sub-optimal retinal drug delivery 
[8]. For these reasons, intravitreal injections are widely used even 
though it is an invasive method of retinal drug delivery. In the case of 
intravitreal drug delivery, it is important to ascertain delivery to the 
retinal target cells and adequate duration of drug action. Consequently, 
novel drug delivery systems are needed for intravitreal drug adminis-
tration [9]. 
Current drug delivery systems for clinical treatment of the posterior 
segment diseases include intravitreal injection of drug solutions and 
implants [10,11]. For example, Ozurdex is a dexamethasone releasing 
injectable, degradable implant that is used to treat macular edema and 
inflammation of the eye [12]. Nonetheless, many implants comprise of 
non-degradable polymers that are used to control drug release for 
several months and might require surgical intervention; limiting their 
wide-spread clinical use [13,14]. Also, particulate based systems for 
intravitreal administration have been investigated [6]. Both implants 
and particulate systems might however obstruct vision and possible 
toxicity arising from polymer degradation products is of concern. Fur-
thermore, their physical size does not allow targeted delivery to the 
retinal cells [5]. Development of alternative drug delivery systems are 
thus needed to meet the therapeutic challenges of retinal diseases. 
Intravitreally administered small molecules are rapidly eliminated 
from the vitreous and they distribute non-specifically to ocular tissues 
and may cause adverse effects, such as increased intraocular pressure 
and cataract associated with corticosteroid treatment [4,15]. One 
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approach to mitigate side effects and rapid elimination of small mole-
cule drugs is to form drug conjugates for targeted delivery and con-
trolled release. Polymeric and antibody drug conjugates have been well 
investigated in the context of cancer therapy [16], but this concept has 
not been extensively explored for ocular drug delivery. A recent report 
introduced hyaluronic acid binding polypeptide chain to successfully 
prolong the half-life of protein drug [17]. We reported a peptide-based 
delivery system for controlled release of peptide cargo (D-peptides) 
within the intra-cellular space of the retinal pigment epithelial cells 
[18]. The peptide-based strategy utilized linkers that were cleaved by 
the enzymes present in the RPE cells to release the cargo. Additionally, 
the peptide-cargo conjugates were stable within the vitreous environ-
ment to avoid premature drug release in the vitreous. The modular 
delivery system consisted of three components: (a) cell penetrating 
peptide to promote intracellular entry, (b) peptide linker with con-
trolled enzymatic cleavage rate and (c) D-peptide cargo. Notably, the 
peptide-based delivery system offers advantages of relative ease of 
synthesis, targeted intracellular delivery and controlled release of cargo 
exploiting intracellular components (enzyme cathepsin D) of the retinal 
cells. 
In the present study, we demonstrate the potential of the modular 
peptide-based system for the retinal cellular delivery of dexamethasone. 
Dexamethasone is used in ophthalmology to treat ocular inflammations 
and uveitis in both anterior and posterior segments [19], but the use of 
dexamethasone is associated with side-effects, such as increased in-
traocular pressure and cataract formation [20]. Consequently, to 
overcome such effects, alternative delivery systems are desired for 
controlled or sustained release of dexamethasone at the site of action. 
We report here targeted and controlled release of dexamethasone from 
modular peptide-based delivery system within the retinal pigment 
epithelial cells. 
2. Materials and methods 
2.1. Design and synthesis of conjugates 
2.1.1. Design of peptide-dexamethasone conjugates 
A set of three peptide-dexamethasone conjugates (Scheme 1) were 
synthesized based on our previous findings [18]. The conjugates con-
sisted of three components: (1) N-terminal cell penetrating peptide 
(CPP) to promote intracellular entry, (2) an enzyme cleavable peptide- 
based linker (PCL) and (c) dexamethasone conjugated to the C-terminal 
of PCL via hydrazone linkage. Fluorescent Alexa 488 dye was cova-
lently attached to the conjugates. The differences between the three 
conjugates are entirely attributed to the CPPs with varying number of 
positively charged residues (Arg/Lys) (Scheme 1). Dex-1 contains a 
cationic CPP (from HIV-1 Tat) with 7 Arg/Lys residues, Dex-2 contains 
2 Lys/Arg residues in the CPP sequence and Dex-3 consists of a 
hydrophobic CPP sequence [21]. 
2.1.2. Peptide synthesis 
The peptide-dexamethasone conjugates (Scheme 1, Table 1) were 
synthesized by Peptide Synthetics Peptide Protein Research Ltd. 
(Hampshire, UK). In general, the peptides were synthesized using solid 
phase peptide synthesis. Chlorotrityl resin (Iris, 300 mg, per sequence, 
200 mesh, 1.1 mmol/g chloride loading) was functionalized by mixing 
the resin in dry dimethyl formamide (DMF) with hydrazine (0.5 
equivalents) for 30 min. Un-functionalized sites on the resin were 
capped with a brief treatment of methanol in DMF containing DIPEA 
(0.25 ml), to obtain a working substitution level of 0.3–0.5 mmol/g. 
The hydrazine resin obtained was then employed to generate peptides 
with the desired sequence via an automated peptide synthesizer 
(Symphony, Protein Technologies Inc. Arizona) using the Fmoc chem-
istry method [22] with Fmoc amino acids appropriately side chain 
protected (Matrix Innovation). After the synthesis, the hydrazide pep-
tides were cleaved from the solid support and their side chain pro-
tecting groups were removed with trifluoroacetic acid (TFA) cocktail 
containing 2% isopropyl silane, 1% phenol and 2% ethane dithiol for 
2 h. The TFA solution was filtered from the resin and the crude peptides 
precipitated by adding diethyl ether. The precipitated peptides were 
pelleted by centrifugation. 
The peptides were purified by RP-HPLC on a Varian system 
equipped with a C-18 preparative Axia column (Phenomenex) at room 
temperature, using a Varian 325 UV-detector with a detection wave-
length 225 nm, two 210 Varian pumps with flow rate of 20 ml/min and 
a gradient of 5–55% acetonitrile in 60 min. Peptides were loaded in 
dimethyl sulfoxide (DMSO) to the column and eluted with increasing 
gradient between water (with 0.1% TFA) and acetonitrile (with 0.1% 
TFA). The eluting peptides were visualized with UV absorption and the 
fractions were collected manually. The purity of the product-containing 
fractions was confirmed by LC-MS, combined and freeze-dried. 
For peptide labeling with Alexa 488 dye, a cysteine residue was 
incorporated in the linker sequence between the CPP and PCL (Scheme- 
1). The side chain thiol of the cysteine was used to react with a mal-
eimido-activated form of the Alexa 488 dye (Invitrogen): 5 mg of 
maleimido dye was added to the peptide (5 mg dissolved in 50:50 
DMSO/PBS, pH 7.4, 2 ml). The mixture was stirred until all the peptide 
has been labeled (checked by mass spectrometry). Then, the peptide 
was introduced onto an HPLC column and the labeled peptide was 
eluted as described above. Purified labeled peptide was freeze-dried. 
2.1.3. Synthesis of peptide-dexamethasone conjugates 
The synthesized Alexa-labeled C-terminal peptide hydrazide was 
purified and then condensed with the ketone group of dexamethasone 
to form the hydrazone linked peptide-drug conjugate. In brief, the la-






Scheme 1. Dexamethasone conjugated to 
the C-terminus of CPP-PCL chimeras via a 
hydrazone linkage (red). CPP, PCL se-
quences and dexamethasone are shown in 
black, blue and green, respectively. A short 
flexible linker, Gly-Gly-Ser (shown in 
yellow) was introduced in between the CPP 
and PCL sequences. A cysteine residue was 
introduced after the linker to attach the 
fluorescent dye Alexa 488 to the side chain 
thiol of Cys. Lower case single letter amino 
acid abbreviation refers to a D-amino acid. 
The D-amino acid enhances the sensitivity 
and specificity of the linker for cathepsin D 
mediated cleavage. (For interpretation of 
the references to color in this figure legend, 
the reader is referred to the web version of 
this article.) 
M. Bhattacharya, et al.   Journal of Controlled Release 327 (2020) 584–594
585
acetate buffer (0.1 M, 0.5 ml) was added. A 10-fold molar excess of 
dexamethasone, pre-dissolved in DMSO, was added and the solution 
was stirred at 40 °C for 48 h. A further 10-fold molar excess of dex-
amethasone was added and mixed for another 48 h in case the reaction 
was not complete (as followed by LC/MS, Phenomenex C18 kinetex 
core-shell column, 50 × 4.6 mm, 2.6 μm internal diameter with a 100 Å 
pore size, step gradient of acetonitrile). When the reaction was com-
pleted (confirmed by LC/MS), the product was isolated by RP-HPLC as 
mentioned above. 
2.2. In vitro stability and binding studies 
2.2.1. Stability of conjugates in porcine vitreous 
Stability of the peptide-dexamethasone conjugates against de-
gradation in porcine vitreous was determined. Porcine eyes were pro-
cured from a local slaughterhouse and the eyes were kept on ice bath 
during the isolation of vitreous humor. The eyes were first cleansed of 
extra-ocular material and dipped in 70% ethanol. The eyes were opened 
by incision with a dissecting knife and the clear vitreous humor was 
separated gently from the retina. Isolated vitreous humor was homo-
genized, centrifuged (3200 ×g) for 1 h at +4 °C and the supernatant 
was sterile-filtered using a 0.22 μm filter to remove cellular debris and 
possible microbial contamination. The vitreous was stored at −80 °C. 
For stability studies, 10 μM of the conjugates were mixed with porcine 
vitreous humor with 1% antibiotics (penicillin/streptomycin; Gibco) in 
Eppendorff tubes. Each time point had designated separate tube. The 
tubes were incubated at 37 °C and release of dexamethasone from the 
conjugate was monitored using ultra-performance liquid chromato-
graphy tandem mass spectrometry (UPLC-MS/MS). Before the mass 
analysis, the mixture was subjected to acetonitrile clean-up. Three vo-
lumes of cold acetonitrile were added to each sample, vortexed and 
stored at room temperature for 1 h. The samples were centrifuged for 
10 min at 12,000 ×g to remove precipitates. The supernatant was 
freeze-dried and stored at −20 °C for further UPLC-MS/MS analysis. 
Liquid chromatography separation was carried out using Waters 
Acquity UPLC instrument (Waters, MA, USA) coupled with Waters 
Acquity UPLC BEH Shield RP18 (2.1 × 100 mm, 1.7 μm) column at 
50 °C. The mobile phase consisted of 0.1% of formic acid in ultrapure 
water (A) and 100% of LC-MS grade acetonitrile (B). Freeze dried 
samples were diluted with cold 30% LC/MS grade acetonitrile 
(Chromasolv™, Honeywell, Seelze, Germany) in ultrapure water, and 
vortexed prior to the analysis. Mass spectrometry measurements were 
carried out using a Waters Xevo triple quadrupole mass spectrometer 
(TQ-S) equipped with an electrospray (ESI) source. Samples were 
analyzed on positive ionization mode and multiple reaction monitoring 
(MRM) mode was used for quantification. Minimum of five calibration 
curve points in the range 0.005–250 nM were used for quantification of 
the dexamethasone. The resulting data were analyzed with Waters 
MassLynx software V4.1. 
2.2.2. Interactions of conjugates with the vitreous humor 
Binding of peptide-dexamethasone conjugates to the porcine vitr-
eous was studied by microscale thermophoresis (MST). MST is a bio-
physical technique used to study the molecular interaction by mon-
itoring the directed movement of fluorescently labeled molecule in a 
temperature gradient [23–25]. The MST measurements were performed 
using a Monolith NT.115 instrument from Nanotemper Technologies 
(München, Germany) with MST grade premium NT.115 capillaries. 
Literature precedence's suggest that cationic particulate systems in-
teract with hyaluronic acid, HA (anionic hydrophilic polymer), a pri-
mary component of the vitreous [26,27]. Consequently, for the posi-
tively charged peptide-dexamethasone conjugates, we postulate that 
they interact with vitreous HA. The concentration of HA in porcine 
vitreous (stock solution) was considered to be 1600 nM based on esti-
mates from earlier reports [28,29]. The unlabeled vitreous (Section 
2.2.1) was serially diluted and mixed with 100 nM fluorescently labeled 
conjugates in MST optimized buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 10 mM MgCl2, 0.05% Tween-20). HA concentration range in the 
assay mixture was 0.02–800 nM. All the samples were centrifuged at 
14,000 ×g for 10 min to remove any aggregates present. The samples 
were loaded into Monolith NT.115 capillaries after incubation at room 
temperature for 5 min and MST measurements were performed at 22 °C 
by using nano-blue excitation with LED excitation power 20% and 80% 
for Dex-2 and 3 respectively, infrared laser (MST power) was set to 
medium. Data analyses were performed using Nanotemper analysis 
software. For determination of the dissociation constant (Kd) of the 
binding interaction, normalized fluorescence values were plotted 
against log of the estimated hyaluronic acid concentration in the por-
cine vitreous using GraphPad Prism software (version7.04, San Diego, 
CA, USA). 
2.2.3. Binding of Dexamethasone-Arginine fragment to glucocorticoid 
receptor 
Microscale thermophoresis (MST) technique was used to study the 
binding interaction of Dexamethasone-Arginine (Dex-Arg) fragment 
and glucocorticoid receptor. The MST measurements were performed 
using a Monolith NT.115 instrument from Nanotemper Technologies 
with MST grade premium NT.115 capillaries. Purified human gluco-
corticoid receptor (hGR, Abcam) was labeled with Lightning-Link® 
Rapid Alexa Fluor® 488 kit (Expedeon) following manufacturer's in-
struction. The labeling kit enables direct conjugation of Alexa Fluor® 
488 with the available amine groups in the hGR. Unlabeled Dex-Arg 
fragment was serially diluted from 0.5 μM to 0.015 nM in MST opti-
mized buffer and titrated into a fixed concentration of labeled hGR 
(10 nM). All the samples were centrifuged at 14,000 ×g for 10 min to 
remove aggregates. The samples were loaded into Monolith NT.115 
premium capillaries after incubation at room temperature for 10 min 
and MST measurements were performed at 22 °C by using 5% LED 
power and medium MST power. Data analyses were done using 
Nanotemper analysis software. Normalized fluorescence values were 
plotted against the log of Dex-Arg fragment concentration using 
GraphPad Prism software (version7.04, San Diego, CA, USA). 
2.2.4. Molecular docking to glucocorticoid receptor 
For computational modeling of the Dex-Arg fragment, we utilized 
the crystal structure of human glucocorticoid receptor (hGR) in com-
plex with dexamethasone (PDB id: 1M2Z). The protein-ligand complex 
exists as a dimer in the crystal structure. Only a single chain of the 
receptor was considered for molecular docking. Dexamethasone and 
other small molecules (including water) were removed from the ligand- 
Table 1 
Peptide-dexamethasone conjugates and corresponding fragments after intracellular cleavage.       
Conjugate # Structure of the conjugates Released fragment Fragment mass 
Calculated Detected (MH+1 Mono)  
Dex-1 NH2-GRKKRRQRRPPQGGSC(Alexa 488)KGKPILFFRLKr-NH-N=Dex r-NH-N=Dex 562.6 563.6 
Dex-2 NH2-FNLPLPSRPLLRGGSC(Alexa 488)KGKPILFFRLKr-NH-N=Dex r-NH-N=Dex 562.6 563.6 
Dex-3 NH2-AAVLLPVLLAAPGGSC(Alexa488)KGKPILFFRLKr-NH-N=Dex r-NH-N=Dex 562.6 563.6 
Fragments were detected by LC-MS. r denotes D-Arginine residue.  
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binding domain to generate the native structural model of the hGR as 
the target protein. 3D-structural models of dexamethasone and Dex-Arg 
fragment were built by using MarvinSketch (version 20.11.0; http:// 
www.chemaxon.com). CB-Dock server [30] was used to predict the 
binding modes of dexamethasone and Dex-Arg fragment with the hGR. 
The best docking results were then compared with the crystal structure 
complex and visualized using UCSF Chimera package [31]. 
2.3. Cell culture and cell based assays 
ARPE-19 cells (human retinal pigment epithelial cell line, ATCC 
CRL-2302) were cultured in Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F-12) supplemented with 10% fetal 
bovine serum (Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin 
and 2 mM L-glutamine (Gibco). The cells were cultured in a T-75 flask at 
37 °C in a 7% CO2 atmosphere. The cells were sub-cultured once a week 
until they reached 80% confluency. The culture media was changed 
twice a week. 
2.3.1. Cytotoxicity 
Cytotoxicity of the peptide-dexamethasone conjugates was eval-
uated using MTT assay as previously described [32]. Briefly, the cells 
were seeded in 96-well plates at a density of 20,000 cells per well in 
150 μl of cell growth medium. After over-night incubation, the cells 
were washed with PBS. Peptides at various concentrations 
(0.01–100 μM) in complete cell growth medium (100 μl) were added to 
each well for incubation (5 h at 37 °C, 7% CO2). Poly-L-lysine (PLL) 
treated and untreated cells served as negative and positive controls, 
respectively. After incubation, the medium was aspirated, the cells were 
washed with PBS and 150 μl of growth medium was added to the cells. 
Then, the cells were washed with PBS after incubation of 24 h. A 
mixture of 90 μl of complete growth medium and 10 μl of 5 mg/ml of 
MTT solution was added to the wells and the plates were incubated for 
4 h at 37 °C. After incubation, 100 μl of 10% sodium dodecyl sulfate 
(Merck) in 0.01 M HCl (Sigma-Aldrich) was added to the wells to so-
lubilize formazan crystals followed by overnight incubation at 37 °C. 
Formazan was quantified by measuring absorbance at 570 nm using a 
spectral scanning multimode plate reader (Varioskan Flash, Thermo 
Scientific). Viability of the treated cells was compared to the untreated 
control cells. 
2.3.2. Cellular uptake 
ARPE-19 cells were seeded on a 24-well Sensoplate polystyrene flat 
glass bottom black plates (Greiner bio-one) at a density of 25,000 cells/ 
well and incubated at 37 °C with 7% CO2 for 24 h. The cells were rinsed 
twice with 2 ml HBSS buffer (Gibco, supplemented with 10 mM Hepes, 
pH 7.4) and equilibrated in the same buffer for 30 min at 37 °C. The 
cells were then treated with labeled peptide-dexamethasone conjugates 
(5 μM) for 1 h at 37 °C. Afterwards cells were washed thrice with HBSS 
buffer to remove unbound and surface bound conjugates followed by 
plasma membrane staining with CellMask™ Deep Red (Invitrogen) for 
30 min at room temperature in dark. The nuclei were stained with 1 μg/ 
ml Hoechst 33342 for 10 min at room temperature in dark, washed with 
HBSS to remove excess stain and live cells were imaged immediately 
using Cytation 5 cell imaging multimode reader (BioTek). Images were 
taken using 40× plan fluorite phase objective (1,320,518, Olympus) 
and processed with Gen5 Image Prime software, version 3.08. All 
images were obtained under identical conditions; the cell nucleus, the 
cytoskeleton and the conjugates were visualized in blue, deep red and 
green, respectively. 
2.3.3. Intracellular drug release 
Intracellular release of dexamethasone from the peptide-dex-
amethasone conjugates was studied using sub-confluent ARPE-19 cells 
that were cultured on 6 well plate. The cells were seeded at a density of 
500,000 cells/well and experiments were performed 48 h after the cells 
had achieved sub-confluent monolayer. The conjugates were dissolved 
in complete growth medium (DMEM/F-12; supplemented with 100 U/ 
ml streptomycin/penicillin and 2 mM L-glutamine). Prior to the ex-
periment, the cells were washed twice with PBS (Gibco) and incubated 
with the conjugates (5 μM/well) for 1 h at 37 °C. After 1 h, the cells 
were washed thrice with PBS to remove unbound and surface bound 
conjugates. The cells were detached from the bottom of the wells using 
TrypLE Express enzyme (Gibco) and the number of cells harvested from 
each well was determined. Lysis buffer (Biovision) was added to the 
cells collected from each well and the cells were lysed following the 
manufacturer's instructions. Clear cell lysate from each well was col-
lected into low binding Eppendorf tubes and stored on ice before UPLC- 
MS analyses. 
2.4. LC-MS analyses 
To identify the molecule released from the conjugates in the cells 
(Section 2.3.3), three volumes of cold acetonitrile were added to the 
cell lysate samples, vortexed and stored at room temperature for 1 h. 
The samples were centrifuged for 10 min at 12,000 ×g to remove 
precipitates. The supernatant was freeze-dried and stored at −20 °C for 
further UPLC-MS analysis. 
UPLC-MS profiling analyses were carried out with Orbitrap-MS 
System (Q Exactive Focus, Thermo Fisher, Bremen, Germany) using 
reversed phase (RP) chromatography with positive mode ESI. The RP 
separation was performed on a Zorbax Eclipse XDB-C18 column 
(100 mm × 2.1 mm, 1.8 μm; Agilent Technologies). The flow rate was 
0.4 ml/min, and gradient elution of 2–100% was used with water with 
0.1% v/v of formic acid (eluent A) and methanol (eluent B). The in-
jection volume was 10 μL and the sample tray was maintained at 4 °C. 
For data acquisition, the mass range was 300–1100 amu and 
320–1200 amu with a resolution of 70,000. Data acquisition and ana-
lysis was conducted with Xcalibur and Freestyle software. 
2.5. Intravitreal pharmacokinetics 
Pigmented 2.5–3.0 kg female Dutch belted rabbits (Linköping, 
Sweden) were used in the study. The animals were housed under 
normal diet at a set temperature of 21 °C, humidity and 12/12 h light- 
dark cycle. All animal experiments were approved by the national 
Animal Experiment Board in Finland. Free dexamethasone was not in-
cluded for in vivo PK studies to limit the number of animals used and 
due to limitations of non-invasive fluorophotometry that was employed 
in the present study. 
2.5.1. Intravitreal injections 
The animals were anesthetized with medetomidine (Domitor vet 
1 mg/ml; Orion Pharma, Espoo, Finland; dose 0.5 mg/kg) and ketamine 
(Ketalar/Ketaminol vet 50 mg/ml; Pfizer Oy Animal Health, Espoo, 
Finland; dose 0.5 ml/kg). Pupils were dilated with tropicamide (Oftan 
Tropicamid 5 mg/ml, Santen Pharmaceutical Co., Ltd., Tampere, 
Finland) and eyes were locally anesthetized with oxybuprocaine (Oftan 
Obucain 4 mg/ml, Santen Pharmaceutical Co., Ltd., Tampere, Finland). 
Viscotears 2 mg/g (carbomer) was used for ocular surface moistening. 
The 31G disposable needle was inserted, about 4.5 mm out of limbus, 
through the sclera into the vitreous and 40 μl of the peptide solution 
with the concentration 125 μM (dose of 5 nmol per eye) was injected 
into the vitreous. After withdrawing the needle, the eyes were covered 
with antibiotic ointment in order to avoid infections (chloramphenicol; 
Oftan Chlora 10 mg/g). Two rabbits were injected with labeled Dex-1 
conjugate and two others with labeled Dex2 conjugate in both eyes 
(n = 4 eyes/peptide). Dex-3 was not included in the pharmacokinetics 
study, as this particular conjugate had too low fluorescence intensity for 
Fluorotron assays. This could be due to internal quenching of the 
fluorescence signal as a consequence of the solution conformation of the 
peptide conjugate. Atipamezole (Antisedan vet 5 mg/ml; 0.2 ml/kg), 
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was used after anesthesia to wake the animals. 
2.5.2. Fluorotron measurements 
In vivo fluorophotometry measurements were performed with ocular 
fluorophotometer (Fluorotron Master, OcuMetrics, CA, USA). The ani-
mals were kept under light sedation (Domitor vet 1 mg/ml; 0.3 ml/kg) 
during the measurements. Baseline autofluorescence values were 
measured prior to the intravitreal injections. After the injections, the 
fluorescence levels in the vitreous and aqueous humor were measured 
daily for 3 days. Bepanthen Eye (sodium hyaluronate 0.15% and dex-
panthenol 2%) was used for eye surface moisturizing during the mea-
surements. The average fluorescence signal of vitreous was calculated 
by averaging in the axial region of eye starting 3 mm anteriorly from 
retina to the posterior edge of the lens. The distance of 3 mm from the 
retina decreases artifacts related to the tailing effect of retinal peak 
[33]. For aqueous humor values, the average of the signal in the middle 
of the compartment was used and calculated using the program of 
Flourotron. GraphPad Prism (version7.04, San Diego, CA, USA) was 
used for fitting concentration vs time curves and calculation of the 
pharmacokinetic parameters. 
3. Results 
3.1. Stability of the conjugates in the vitreous humor 
To investigate the stability of the peptide-dexamethasone con-
jugates in the vitreal environment, the conjugates were incubated with 
porcine vitreous at 37 °C. All three conjugates were chemically stable in 
the vitreous humor. No significant quantities of free dexamethasone 
were detected during the assay period of 6 weeks (Fig. 1). These results 
ensure that the dexamethasone release takes place only after inter-
nalization within the RPE cells. Small quantity of unreacted dex-
amethasone (< 5%) as impurity was present in all the conjugates 
(Fig. 1). 
3.2. Binding of the conjugates to the vitreous humor 
Binding of peptide-dexamethasone conjugates to porcine vitreous 
was evaluated with microscale thermophoresis. Fig. 2 shows the ther-
mophoresis signal from the binding interaction of Alexa 488 labeled 
conjugates (Dex-2 and Dex-3) and HA present in the vitreous humor. 
Normalized fluorescence values (Fnorm) plotted against log of HA 
concentration in porcine vitreous to obtain the binding affinity. The 
dissociation constants (Kd) for the binding of Dex-2 and Dex-3 con-
jugates to the vitreal HA were 13.5 nM and 64.3 nM, respectively. Dex- 
1 conjugate was not included in the study due to its adherence to the 
capillary walls. 
3.3. Cellular uptake 
Internalization of peptide-dexamethasone conjugates to cultured 
ARPE-19 cells was investigated. Fluorescence microscope images shows 
that the conjugates were internalized within the ARPE-19 cells without 
association at the cell surface (Fig. 3). 
3.4. Cytotoxicity 
Fig. 4 summarizes the results of the cytotoxicity assay. ARPE-19 
cells tolerate the conjugates well at the concentration range of 
0.01–5 μM without significant differences among the conjugates. The 
cytotoxicity of free dexamethasone was evaluated and no cell toxicity 
was seen (Supplementary material, Fig. S1). 
3.5. Cellular release of dexamethasone from the conjugates 
Dexamethasone did not release as pure drug from the conjugates. 
Instead, a fragment Dexamethasone-Arginine (r-NH-N=Dex: Dex-Arg), 
with one Arg residue from the PCL was detected linked to the drug. Full 
sequences of the peptide-dexamethasone conjugates, the fragments 
detected in the cell lysate and molecular masses of the detected frag-
ments are shown in Table 1. 
3.6. Binding affinity of Dexamethasone-Arginine fragment to glucocorticoid 
receptor 
Binding of Dex-Arg fragment (0.01 nM to 0.5 μM) to a fixed con-
centration of labeled hGR (10 nM) was studied with thermophoresis 
(Fig. 5). The thermophoresis signal indicates binding of Dex-Arg to hGR 
in a dose dependent manner. 
3.7. Molecular docking of Dexamethasone-Arginine fragment to 
glucocorticoid receptor 
The application of CB-Dock and Chimera visualization elucidated 
the binding modes of dexamethasone and the Dex-Arg fragment. Top 5 
cavity sizes were identified and Vina scores for binding were obtained 
for each of the cavities. The largest identified cavity (sized 690) for 
dexamethasone docking was the same as the LBD in the crystal struc-
ture of the hGR-dexamethasone complex. A structural comparison of 
the docked dexamethasone (best binding score) in the LBD with that 
over in the crystal structure resulted in a near perfect match as evi-
denced by the low r.m.s.d. value of 0.33 Å. This validated the docking 
methodology. The Dex-Arg fragment was similarly docked and the best 
binding orientation (score) in the LBD (cavity sized 690) was con-
sidered. Structural comparisons of the docked Dex-Arg fragment in the 
LBD with dexamethasone bound in the crystal structure complex 
showed a good-fit between the two ligands. A r.m.s.d. value of 1.34 Å 
Dex-3
Time (h)























































Fig. 1. Stability of peptide-dexamethasone conjugates in porcine vitreous. The conjugates were incubated with porcine vitreous and release of dexamethasone upon 
cleavage of the hydrazone bond in the conjugate was followed. 
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Fig. 2. Binding affinities of peptide-dexamethasone conjugates and porcine vitreous. Normalized fluorescence values (Fnorm) plotted against log of HA concentration 
in porcine vitreous to obtain the binding curves and the data fitted to obtain the Kd values. (A) Binding of fluorescently labeled Dex-2 with porcine vitreous, binding 
affinity (Kd) determined to be 13.5 nM (B) Binding of fluorescently labeled Dex-3 with porcine vitreous with a Kd value of 64.3 nM. Error bars represent standard 
error of n = 3 measurements. 
DEX-1                           DEX-2                            DEX-3
(A)
(B)
Fig. 3. Images of uptake of Alexa 488 labeled peptide-dexamethasone con-
jugates (5 μM) in living ARPE-19 cells, determined by Cytation 5 automated 
digital fluorescence imaging system. The peptides were incubated with the cells 
at 37 °C for 1 h. The cell nuclei and the conjugates (Alexa 488 labeled) were 
visualized with blue and green fluorescence respectively (A); cytoskeleton was 
visualized with deep red fluorescence (B). (For interpretation of the references 
to colour in this figure legend, the reader is referred to the web version of this 
article.) 
Conjugate concentration (µM)


























Fig. 4. Cytotoxicity of peptide-dexamethasone conjugates in ARPE-19 cells. 
Cells were treated with conjugates for 5 h and cell viability was evaluated with 
MTT cytotoxicity assay. The data were normalized based on the viability of 
untreated cells. Data are represented as mean  ±  standard deviation (n = 3). 
Fig. 5. Binding interaction of Dex-Arg fragment to human glucocorticoid re-
ceptor. Unlabeled Dex-Arg fragment (0.015 nM to 0.5 μM) was titrated into a 
fixed concentration of labeled hGR (10 nM). The thermophoretic signal (Fnorm) 
plotted as a function of log of Dex-Arg fragment concentration is shown. 
Fig. 6. Structural comparison of the docked Dex-Arg fragment (green) with the 
structural model of dexamethasone (magenta) in complex with hGR (PDB id: 
1M2Z). Residues of the ligand-binding domain have been depicted in dark grey. 
(For interpretation of the references to colour in this figure legend, the reader is 
referred to the web version of this article.) 
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(matching the corresponding non-H atoms of the dexamethasone part of 
the molecule) was observed. Fig. 6 depicts the degree of structural su-
perposition of the docked Dex-Arg fragment with that of the structural 
model of dexamethasone in complex with the hGR (PDB id: 1M2Z). The 
docking results validated that the Dex-Arg fragment binds at the same 
site as dexamethasone on the hGR. 
3.8. In vivo pharmacokinetics 
The results from the three rabbit eyes that received Dex-1 and four 
rabbit eyes that received Dex-2 (Scheme 1) injections intravitreally are 
shown in Fig. 7. The data from the fourth eye that was injected with 
Dex-1 is not included because some complications emerged after the 
injection. Vitreous and aqueous humor fluorescence signals of Dex-2 
from a single rabbit eye (Supplementary Material, Fig. S2) shows a 
concentration gradient at 3 h after intravitreal injection. However, after 
24 h, the conjugate was homogenously distributed in the vitreous (the 
first data point for PK calculations). The concentrations in the vitreous 
humor were approximately one order of magnitude higher than the 
concentrations in the aqueous humor. The vitreous and anterior 
chamber peptide conjugate concentrations were fitted with one-com-
partment model with first order elimination kinetics resulting in the 
elimination half-lives of 29.9  ±  10.0 h and 24.3  ±  5.6 h for Dex-1 
and Dex-2, respectively. The anatomical vitreous volume was used as 
volume of drug distribution to calculate drug clearance (Table 2) (for 
most intravitreal compounds the volume of distribution (Vd) is in the 
range of anatomical vitreal volume [15]): 
=CL V Kd v (1) 
where CL is the vitreal clearance (μl/h), Vd is the anatomical volume of 
vitreous in rabbits (1700 μl) [34] and Kv is elimination constant (h−1) 
from vitreous. The average clearance values of the peptide- 
dexamethasone conjugates from the vitreous were approximately 
40–50 μl/h. 
To further ascertain the elimination route of the peptide-dex-
amethasone conjugates (anterior or posterior) after intravitreal injec-
tion, a method of Maurice and Mishima was used [35,36]. For anterior 
elimination pathway, the Ca/Cv ratio and vitreal elimination half-lives 











where Ca and Cv are the concentrations of the injected molecule in the 
anterior segment and the vitreous, respectively; Kv is elimination con-
stant from vitreous; Vv is the average volume of vitreous compartment 
in rabbit (1700 μl) [34]; f is the aqueous humor flow rate (3 μl/min) 
[37] and t1/2 is elimination half-life of the injected molecule from the 
vitreous. The calculated pharmacokinetic parameters of the peptide- 
dexamethasone conjugates (Dex-1, Dex-2) were in the close vicinity of 
the predicted blue trend line of the relationship in the Eq. (2) (Fig. 8). 
This suggests that the anterior route dominates in the vitreal elimina-
tion of the peptide conjugates. Fig. 8 also suggests that the elimination 
of Dex-1 and Dex-2 from the vitreous takes place as expected on the 
basis of their molecular weights. The elimination of the peptide con-
jugates via the anterior route is in contrast with that of free dex-
amethasone. Posterior clearance from the vitreous has been reported to 
be dominant for free dexamethasone [4]. The higher vitreal clearance 
rate of free dexamethasone (460 μl/h) as compared to the average flow- 
rate of aqueous humor (180 μl/h) also supports the major contribution 
of the posterior route of dexamethasone elimination. 
4. Discussion 
Intravitreal administration of small molecule drugs are associated 































Fig. 7. Fluorophotometric signal versus time graphs of peptide-dexamethasone conjugates. Different symbols represent replicates from individual eyes. Black and red 
symbols correspond to signals from the vitreous and aqueous humor, respectively. (For interpretation of the references to colour in this figure legend, the reader is 
referred to the web version of this article.) 
Table 2 
Vitreal pharmacokinetic parameters of the conjugates after intravitreal injection.        
Elimination half-life (h) Elimination rate constant (h−1) Vitreal clearance (μl/h) Ca/Cv ratio  
Dex-1     
Eye-1 31.7 0.021 35.7 0.16 
Eye-2 19.2 0.036 61.2 0.42 
Eye-3 38.90 0.017 28.9 0.36 
Average  ±  SD 29.9  ±  10.0 0.024  ±  0.010 41.9  ±  17.0 0.31  ±  0.14 
Dex-2     
Eye-1 19.9 0.034 57.8 0.20 
Eye-2 20.8 0.033 56.1 0.21 
Eye-3 32.3 0.021 35.7 0.22 
Eye-4 24.1 0.028 47.6 0.29 
Average  ±  SD 24.3  ±  5.7 0.029  ±  0.005 49.3  ±  10.1 0.23  ±  0.04 
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with disadvantages, such as fast elimination rate, non-specific dis-
tribution to various ocular tissues and require frequent dosing [6,15]. 
Development of long acting and tissue specific drug delivery systems 
are needed to overcome such challenges. Polymer-drug conjugates (i.e. 
polymeric prodrugs) offer several potential advantages: increased so-
lubility, prolonged drug retention, and targeted delivery of the ther-
apeutics [39,40]. Although such approaches have been explored in the 
field of anticancer therapy [16,41]; their utility in the context of ocular 
drug delivery has been only sparsely investigated [18]. Conjugates are 
interesting option in intravitreal dug delivery, because they can be 
administered as clear solutions, and pharmacokinetics can be optimized 
in terms of cellular drug delivery and duration of action. 
Dexamethasone is a corticosteroid that is used to treat inflammatory 
conditions in the anterior and posterior segments [19,42]. Intravitreal 
dexamethasone injections have been used to treat posterior segment 
inflammation, macular edema and neovascular macular degeneration 
[43] but short half-life of dexamethasone in the vitreous humor (≈ 3 h) 
suggests that frequent intravitreal injections would be required to 
maintain levels of therapeutic concentration [44,45]. Therefore, dex-
amethasone has been delivered to the vitreous as biodegradable im-
plants and coarse suspensions but these modes of drug delivery may 
interfere with vision and require larger needle or applicator for in-
travitreal placement. These approaches prolong duration of drug action 
without improvement in the drug distribution profiles. As such, typical 
adverse effects of corticosteroids (elevation of intraocular pressure, 
cataract formation) are unavoidable. In this study, we have explored a 
modular peptide-based delivery system for prolonged vitreal retention 
and drug delivery into the retinal pigment epithelial cells. 
The modular delivery system is derived from our previous study 
[18] that demonstrated the release of short model peptides within the 
retinal pigment epithelial cells. The modular construct consists of the N- 
terminus segment for cellular delivery (cell penetrating peptide se-
quence) and a linker peptide that cleaves in intracellular environment. 
Dexamethasone was attached to the C-terminus of the linker peptide 
with hydrazone linkage (Scheme 1). Recent reports suggest that poly- 
cationic surface charge on particles bind electrostatically to the hya-
luronic acid [27]. Li and co-workers reported the use of cationic na-
noparticles, coated with L-Arg, as ocular drug delivery system with 
prolonged vitreal half-life [46]. In the design of our modular delivery 
system, we hypothesized to exploit this information. The N-terminus 
sequences were varied to contain differing amounts of positive charge 
to serve dual purpose: intracellular localization and vitreal retention by 
interactions with the vitreal components. Binding to hyaluronic acid in 
the vitreous is expected to slow down the vitreal diffusion of the 
modular peptide conjugates resulting in increased retention time and 
low clearance. Indeed, the interaction studies of peptide-dex-
amethasone conjugates with porcine vitreous revealed that the Dex-2 
conjugate with higher number of positive charges has higher binding 
affinity compared to Dex-3 conjugate (Fig. 2). The apparent Kd values 
are 13.5 nM and 64.3 nM for Dex-2 and Dex-3 conjugates, respectively. 
Plots of vitreal elimination half-life and aqueous/vitreous con-
centration ratios for the peptide-dexamethasone conjugates [36] 
(Fig. 8) reveal that the anterior route is their main elimination pathway. 
Diffusion in the vitreous is a critically important parameter in the 
anterior elimination of intravitreal compounds [6]. Binding to the 
hyaluronic acid is expected to prolong intravitreal half-life. A recent 
study reported 3–4 fold increase in half-life of a protein when hya-
luronic acid binding polypeptide sequence of 97 amino acids was fused 
to the structure [17]. In our study, the peptide-dexamethasone con-
jugates showed 8–10 fold increase in the vitreal half-life (24–30 h) as 
compared to the half-life of dexamethasone solution (3 h) [44,47]. This 
is due to the reduced elimination of dexamethasone across the blood 
ocular barriers. Fig. 8 demonstrates that the anterior elimination in the 
rabbit eyes was as expected based just on the molecular weight even 
though the peptides bind to hyaluronic acid. This may be explained by 
the binding equilibria. We used Coffey's approach [48,49] to simulate 
the impact of hyaluronic acid binding on vitreal drug elimination (for 
details, see Supplementary Material). After an injection of 5 nmol of 
peptide-dexamethasone conjugate into the vitreous, the initial con-
centration of the compound in the rabbit vitreous is about 3000 nM 
(approx. Volume 1.5 ml). Most of the conjugate is in free form after 
injection until ≈80% of the dose has been eliminated from the vitreous 
(Fig. 9A). The fraction of bound peptide increases at low concentrations 
(< 600 nM) (Fig. 9A) and half-life will increase significantly only at 
concentrations below 300 nM (Fig. 9B). These estimates were obtained 
based on binding profile (MST studies) data with the porcine vitreous. 
However, the impact of binding of hyaluronic acid on conjugate 
clearance is expected to be rather small in the rabbit vitreous as it has 
lower hyaluronic acid concentration than the pig vitreous [50,51]. 
Apparently, higher affinity and/or smaller doses are required for fur-
ther prolongation of the vitreal retention. 
Stability in the vitreous is one of the key requirements for the 
Fig. 8. Vitreal elimination half-life vs aqueous/vitr-
eous concentration ratio of the peptide-dex-
amethasone conjugates following intravitreal injec-
tion in rabbit. Dex-1 and Dex-2 parameters falls in 
the vicinity of the blue trend line and are consistent 
with the other compounds with different molecular 
weight suggesting that the anterior pathway is the 
main route of their elimination. The data sources are 
as follows: sucrose (Suc) [38], FD-10.5, FD-67 and 
FD-157 [36]. The mean molecular weights of FITC- 
dextrans (FD) are 10.5 kD, 67 kD, respectively. The 
molecular weight of sucrose (Suc) is 0.342 kD. Dex-1 
and Dex-2 has molecular weight of 4.43 and 4.29 kD, 
respectively. (For interpretation of the references to 
colour in this figure legend, the reader is referred to 
the web version of this article.) 
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intravitreal applicability of modular drug delivery systems. Ex vivo 
stability data reveal that the dexamethasone-peptide conjugates were 
chemically stable for over 6 weeks in the porcine vitreous, suggesting 
that no significant enzymatic cleavage by the peptidases takes place in 
the vitreous humor. Thus, the peptide-dexamethasone conjugates stay 
intact until delivered to the intracellular environment in the retina. In a 
recent report, Matter et al. (2019) suggest that dexamethasone is not 
stable in water solutions [52]. It is noteworthy that only minimal 
concentrations of free dexamethasone (mostly residual amounts from 
conjugate synthesis) were seen in the vitreal incubation studies of 
6 weeks. Consequently, degradation product levels, if any, is expected 
to be negligible. Furthermore, the available time for any degradation is 
only a few days based on in vivo kinetics (Fig. 7). 
We postulate that the modular delivery system has potential ther-
apeutic benefits, because the drug is released within the cells. 
Therefore, this may enable effect at lower dose and reduced drug dis-
tribution to the off-target cells, which may reduce adverse effects of the 
corticosteroid. This principle may be applicable also to other drugs. 
Furthermore, cellular internalization and drug release in the retinal 
pigment epithelial cells might turn these cells as reservoirs for drug 
release to the neighboring cells [18]. Many diseases of the posterior 
segment of the eye, such as age-related macular degeneration and 
proliferative vitreoretinopathy, have a common therapeutic target cell, 
the retinal pigment epithelium [53–55]. To this effect, the modular 
peptide-based delivery system meets the key objective of being able to 
release dexamethasone within the retinal pigment epithelial cells. 
Larger sized protein molecules, such as, the ciliary derived neurotropic 
factor (CNTF; mol wt. 23 kDa) is known to permeate into the retina 
[56]. We therefore postulate that the smaller sized peptide conjugates 
(mol wt. 4.5 kDa) will easily permeate across the inner limiting mem-
brane to the retina. The peptide-dexamethasone conjugates demon-
strated significant cellular uptake, aided by the N-terminal cell pene-
trating peptide (Fig. 3) and dexamethasone release by cathepsin D 
mediated enzymatic cleavage of the peptide linker. The released frag-
ment Dex-Arg is in accordance with results from our previous study on 
sequence-activity relationship of the peptide based linkers [18]. The 
fragment Dex-Arg binds to the glucocorticoid receptor as evidenced by 
computational and experimental approaches. 
The focus and scope of the present work was to highlight and de-
monstrate the utility of our modular peptide-based drug delivery 
system for application in ocular diseases. Although the fluorescence 
based technique, Fluorotron, does not monitor the levels of dex-
amethasone or Dex-Arg fragment in the vitreous or retina in vivo; data 
suggests that Dex-Arg fragment is generated in the retina (RPE cells). 
Chemical quantitation of all relevant molecular species will be a topic 
of future studies with promising conjugate(s). 
Importantly, modular peptide conjugates are rather small mole-
cules. This is important for retinal permeation across the inner limiting 
membrane [6] to the retinal layers. Secondly, these are soluble 
molecules, allowing injection of transparent solutions. Thirdly, the 
conjugates are based on endogenous components (i.e. amino acids) 
which reduces the risk of toxicity. In addition, manufacturing of in-
jectable solutions is less complex than production of particle based 
delivery systems. 
5. Conclusions 
We have shown the potential utility of a modular peptide-based 
delivery system for the retinal delivery of dexamethasone. The system is 
stable in the vitreous, internalizes within the retinal pigment epithelial 
cells and releases the drug after enzymatic cleavage of the peptide 
based linker. The modular peptide systems are promising candidates for 
ocular drug delivery and should be further optimized. 
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